United Therapeutics (UTHR) Change in Acquisitions & Divestments (2009 - 2026)

United Therapeutics has disclosed Change in Acquisitions & Divestments across 18 years of filings, most recently posting $269.0 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $269.0 million, down 56.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 25.83% YoY), and the FY2025 annual result was $1.6 billion, up 3.05% from the prior year.
• Change in Acquisitions & Divestments came in at $269.0 million for Q1 2026 at United Therapeutics, up from -$277.7 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $1.6 billion in Q3 2023 to a low of -$1.6 billion in Q4 2023.
• The 5-year median for Change in Acquisitions & Divestments is $356.5 million (2024), against an average of $199.6 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 30064.0% in 2022 and surged 564.16% in 2023, its largest moves.
• United Therapeutics' Change in Acquisitions & Divestments stood at -$749.1 million in 2022, then tumbled by 115.0% to -$1.6 billion in 2023, then soared by 129.68% to $478.0 million in 2024, then plunged by 158.1% to -$277.7 million in 2025, then surged by 196.87% to $269.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $269.0 million (Q1 2026), -$277.7 million (Q4 2025), and $596.0 million (Q3 2025), per Business Quant data.